Patents by Inventor Yvonne Alice Nagel
Yvonne Alice Nagel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12209091Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.Type: GrantFiled: November 25, 2020Date of Patent: January 28, 2025Assignee: Hoffmann-La Roche Inc.Inventors: Martin Duplessis, Annick Goergler, Georg Jaeschke, Buelent Kocer, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Ulrike Obst Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner
-
Patent number: 11708354Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.Type: GrantFiled: November 24, 2020Date of Patent: July 25, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Martin Duplessis, Georg Jaeschke, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Antonio Ricci, Daniel Rueher, Sandra Steiner
-
Publication number: 20230054473Abstract: The application relates to (106) specific heterocyclic compounds comprising a thiazole ring, an indazol and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole system, to pharmaceutical compositions containing them and their medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.Type: ApplicationFiled: June 19, 2020Publication date: February 23, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
-
Publication number: 20230057891Abstract: The application provides a compound having the general formula (I) wherein R1, R2, R3 and R4 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: December 18, 2020Publication date: February 23, 2023Applicant: Hoffmann-La Roche Inc.Inventors: David Stephen HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Antonio RICCI
-
Publication number: 20230034696Abstract: The application provides a compound having the general formula (I) or a pharmaceutically acceptable salt thereof, compositions including the compound and methods of using the compound. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: December 18, 2020Publication date: February 2, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Antonio RICCI
-
Publication number: 20220315591Abstract: The invention provides novel compounds as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: June 19, 2020Publication date: October 6, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David Stephen HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Roger David NORCROSS, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
-
Publication number: 20220315577Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R3, R4, R5 and R10 are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: June 19, 2020Publication date: October 6, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Antonio RICCI, Daniel RUEHER, Sandra STEINER
-
Publication number: 20220315592Abstract: The application relates to a compound of formula (I) containing a thiazole ring, an indazol ring and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole ring system, to pharmaceutical compositions containing it and its medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.Type: ApplicationFiled: June 19, 2020Publication date: October 6, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
-
Publication number: 20220315593Abstract: The application relates to 6 specific heterocyclic compounds, pharmaceutical compositions containing them and their medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.Type: ApplicationFiled: June 19, 2020Publication date: October 6, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
-
Publication number: 20220135571Abstract: The invention provides novel compounds as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: December 21, 2021Publication date: May 5, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo Dolente, Annick Goergler, Georg Jaeschke, Bernd Kuhn, Christa Ulrike Obst-Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner, David Hewings, Yvonne Alice Nagel
-
Publication number: 20220112199Abstract: The invention provides novel a compound having the general formula (I) as described herein, compositions including the compound and methods of using the compound.Type: ApplicationFiled: December 21, 2021Publication date: April 14, 2022Inventors: Cosimo Dolente, Annick Goergler, David Hewings, Georg Jaeschke, Bernd Kuhn, Yvonne Alice Nagel, Roger David Norcross, Christa Ulrike Obst-Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner
-
Patent number: 11117890Abstract: The present invention provides substituted isoindole compounds which are selective allosteric EGFR inhibitors, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances, generally of Formula: or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 2, 2019Date of Patent: September 14, 2021Assignee: Hoffman La-Roche Inc.Inventors: Georg Jaeschke, Antonio Ricci, Daniel Rueher, Sandra Steiner, Martin Duplessis, Yvonne Alice Nagel, Bernd Kuhn
-
Publication number: 20210079005Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.Type: ApplicationFiled: November 25, 2020Publication date: March 18, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Martin Duplessis, Annick Goergler, Georg Jaeschke, Buelent Kocer, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Ulrike Obst Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner
-
Publication number: 20210070739Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.Type: ApplicationFiled: November 24, 2020Publication date: March 11, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Martin Duplessis, Georg Jaeschke, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Antonio Ricci, Daniel Rueher, Sandra Steiner
-
Patent number: 10882848Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.Type: GrantFiled: June 21, 2019Date of Patent: January 5, 2021Assignee: Hoffmann-La Roche, Inc.Inventors: Martin Duplessis, Georg Jaeschke, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Antonio Ricci, Daniel Rueher, Sandra Steiner
-
Publication number: 20200361930Abstract: The present invention provides compounds that cause specifically the degradation of EGFR via the targeted ubiquitination of EGFR protein and subsequent proteasomal degradation. The present compounds are useful for the treatment of various cancers.Type: ApplicationFiled: August 4, 2020Publication date: November 19, 2020Applicants: Hoffmann-La Roche Inc., C4 Therapeutics, Inc.Inventors: Martin Duplessis, Georg Jaeschke, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Antonio Ricci, Daniel Rueher, Sandra Steiner
-
Publication number: 20200308171Abstract: Present invention provides bifunctional compounds that comprise an E3 Ubiquitin Ligase moiety that is linked to a moiety that inhibit EGFR, where the target protein can be proximate to the ubiquitin ligase to effect degradation of said protein. Present compounds are useful for the treatment of various cancers.Type: ApplicationFiled: June 16, 2020Publication date: October 1, 2020Applicants: Hoffmann-La Roche Inc., C4 Therapeutics, Inc.Inventors: Georg Jaeschke, Bernd Kuhn, Antonio Ricci, Daniel Rueher, Sandra Steiner, Yvonne Alice Nagel, Martin Duplessis, Kiel Lazarski, Yanke Liang
-
Publication number: 20200102299Abstract: The present invention provides compounds which are selective allosteric inhibitors of TMLR, TMLRCS, LR, LACS containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.Type: ApplicationFiled: December 2, 2019Publication date: April 2, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Georg Jaeschke, Antonio Ricci, Daniel Rueher, Sandra Steiner, Martin Duplessis, Yvonne Alice Nagel, Bernd Kuhn
-
Publication number: 20190308955Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.Type: ApplicationFiled: June 21, 2019Publication date: October 10, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Martin Duplessis, Georg Jaeschke, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Antonio Ricci, Daniel Rueher, Sandra Steiner
-
Patent number: 10227390Abstract: Provided herein are stabilized ?-CT polypeptides comprising an alpha-helical segment, and wherein the polypeptide is of Formula (I-1) or Formula (I-2): Rf—[XAA]s—XA1—XA2—XA3—XA4—XA5—XA6—XA7—XA8—XA9—XA10—XA11—XA12—XA13—XA14—[XAA]t—Re (I-1) Rf—[XAA]s—XC1—XC2—XC3—XC4—XC5—XC6—XC7—XC8—XC9—XC10—XC11—XC12—XC13—XC14—XC15—XC16—XC17—XC18—XC19—XC20—[XAA]t—Re (I-2) wherein the ?-CT polypeptide binds to the insulin receptor, and wherein the ?-CT polypeptide includes at least one staple (i.e. two cross-linked amino acids) and/or at least one stitch (i.e. three cross-linked amino acids). Further provided are insulin analogs including the stapled or stitched ?-CT polypeptides, pharmaceutical compositions thereof, methods of use, e.g., methods of treating a diabetic condition or complications thereof.Type: GrantFiled: June 13, 2014Date of Patent: March 12, 2019Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Gregory L. Verdine, Gerard Hilinski, Rebecca Yue Liang, Yvonne Alice Nagel, Minyun Zhou